News | Vascular Access | September 20, 2016

Teleflex Promotes Rise of the Vascular Access Specialist at AVA 2016 Congress

Company features new online clinical education platform, hosts several symposia on vascular access technology

Teleflex, AVA 2016 Congress, Association for Vascular Access

September 20, 2016 — Teleflex Inc. recently displayed its vascular access technologies and a new educational platform focused on the rise of the vascular access specialist at the 30th Annual Scientific Meeting of the Association for Vascular Access (AVA). The meeting was held Sept. 16-19 in Orlando, Fla.

Teleflex unveiled the Teleflex Academy, a new online clinical education platform. The booth educational experience for the Teleflex Academy at this year’s AVA focused on every aspect of vascular access. Teleflex believes that quality education is the first step in fostering the expansion of skills and helping to shape clinical practice.

Teleflex also launched the Arrow Midline with Chlorag+ard Technology, adding to the family of antithrombogenic and antimicrobial protected catheters.

The company offered its popular Vascular Access Procedural Cadaver Lab onsite, training on many different vascular access procedures. There were also clinical education activities at its booth, where models were used to demonstrate the full range of the company’s vascular access devices.

At the breakfast symposium, “Rising to the Challenge: How Vascular Access Specialists Started Placing CVCs,” attendees were educated on the importance of the evolution of the vascular access specialist. This course highlighted the experiences of clinicians who have made the journey to expand their roles to place central venous catheters, and described the clinical process and materials needed to develop a vascular access team.

The platinum showcase symposium, “Locking the Lumen…Consider the Solutions!” reviewed why given today’s medical reimbursement risks, facilities must explore all opportunities to reduce potential vascular access complications. Locking solutions could provide an additional layer of protection when used in conjunction with proven protected catheter technology. The presentation addressed catheter colonization, intraluminal colonization, and how locking solutions and protected catheters address these.

The dinner symposium, “Strategy or Risk: the Use of Midline Catheters”, focused on the recent popularity of Midline catheters, the role of a Midline, and how technology could be the key to ensuring Midline success.

For more information: www.teleflex.com

Related Content

Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...
News | Cath Lab | December 18, 2019
December 18, 2019 — Cook Medical initiated a recall of its CrossCath Support Catheters in November, which the U.S.
Gallery | Cath Lab | October 31, 2019 | Dave Fornell, Editor
This is a photo essay of the interventional cardiology and structural heart technologies on the expo floor and discus
The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

Technology | Cath Lab | October 28, 2019
Office based labs (OBLs) and ambulatory surgery centers (ASCs) require a fresh perspective from imaging vendors.
Marco Costa, M.D., Ph.D., MBA, president, UH Harrington Heart and Vascular Institute, performing a cath lab procedure.

Marco Costa, M.D., Ph.D., MBA, president, UH Harrington Heart and Vascular Institute, performing a cath lab procedure.

News | Cath Lab | October 28, 2019
October 28, 2019 — Leaders within University Hospitals and the Harrington Heart and Vascular Institute had a vision t
OmniVision Announces Guinness World Record for Smallest Image Sensor

OmniVision's OVM6948 CameraCubeChip, a fully packaged, wafer-level camera module measuring 0.65mm x 0.65mm x 1.158mm, built on OmniVision's OV6948, winner of the Guinness World Record for “The Smallest Image Sensor Commercially Available.”

News | Cath Lab | October 22, 2019
October 22, 2019 — OmniVision Technologies Inc.
People watch the presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., live in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long term surgical outcomes. #TCT2019

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes. 

Feature | Cath Lab | October 03, 2019
October 3, 2019 – Five-year data from the EXCEL Trial showed patients with left main coronary disease treated with pe
Overlay Init